Cancer Biotech Day One Biopharma Expands to ADCs, Paying $55M to Nab a Phase 1-Ready Drug

Posted
Day One Biopharmaceuticals is adding an antibody drug conjugate to its pipeline, licensing rights to a molecule from MabCare Therapeutics. The MabCare ADC addresses PTK7, a protein found in many types of solid tumors. The post Cancer Biotech Day One Biopharma Expands to ADCs, Paying $55M to Nab a Phase 1-Ready Drug appeared first on MedCity News.

Continue reading at MedCity News »

BioPharma, Daily, Pharma, antibody drug conjugate, cancer, Clinical Trials, Day One Biopharmaceuticals, deals, MabCare Therapeutics